Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2
Abstract Indoxyl sulfate (IS) accumulates in the body in chronic kidney disease (CKD). In the renal proximal tubules, IS excretion is mediated by OAT1/3 and ABCG2. These transporters are inhibited by some hypouricemic agents; OATs by probenecid and benzbromarone, ABCG2 by febuxostat and benzbromaron...
Guardado en:
Autores principales: | Tetsuya Taniguchi, Koichi Omura, Keisuke Motoki, Miku Sakai, Noriko Chikamatsu, Naoki Ashizawa, Tappei Takada, Takashi Iwanaga |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a6860c1db1a4d4487fc7428387fc12b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients
por: Ping-Hsun Wu, et al.
Publicado: (2021) -
Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype.
por: Liesbeth Viaene, et al.
Publicado: (2014) -
Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Sachiho Miyata, et al.
Publicado: (2021) -
Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD)
por: Hee Young Kim, et al.
Publicado: (2017) -
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Kazi Mirajul Hoque, et al.
Publicado: (2020)